Consideration must be given to adverse events that may occur in response to the apheresis procedure and in response to exposure to medicinal products employed (i) to mobilise haematopoietic stem and progenitor cells and (ii) for myeloablative conditioning.
The clinical safety of Casgevy has been evaluated in four open‑label, single‑arm studies (studies 111, and 121 are completed; studies 141, and 151 are on-going) and one on-going long‑term follow‑up study (study 131), in which 123 patients aged 5 years of age and older with transfusion‑dependent β‑thalassemia or sickle cell disease have been treated with Casgevy.
Patients with transfusion‑dependent β‑thalassemia
Summary of the safety profile
Study 111 (patients 12 years and older)
The median (min, max) duration of follow‑up for 56 patients with transfusion‑dependent β‑thalassemia in study 111 after being administered Casgevy, including follow‑up in study 131, was 53.4 (23.2, 82.5) months.
Serious adverse reactions attributed to Casgevy occurred in 2 (3.6%) patients: 1 (1.8%) patient with haemophagocytic lymphohistiocytosis, acute respiratory distress syndrome, idiopathic pneumonia syndrome and headache; 1 (1.8%) patient with delayed neutrophil engraftment and thrombocytopenia.
A life‑threatening serious adverse reaction of cerebellar haemorrhage occurred in 1 (1.8%) patient and was attributed to myeloablative conditioning.
There were not any cases of graft versus host disease, graft failure, or graft rejection, and there were not any deaths.
Tabulated list of adverse reactions
Adverse reactions are listed by MedDRA body system organ class and by frequency. Frequencies are defined as: very common (≥ 1/10) and common (≥ 1/100 to < 1/10). Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.
Tables 1 and 2 list adverse reactions attributed to Casgevy and autologous haematopoietic stem cell transplant complications, respectively, experienced by patients with transfusion‑dependent β‑thalassemia in clinical studies with Casgevy.
Table 1: Adverse reactions attributed to Casgevy in patients with transfusion‑dependent β‑thalassemia in study 111 (N=56)
| System organ class | Very common (≥10%) | Common (≥1% ‑ <10%) |
| Blood and lymphatic system disorders | Lymphopenia *, † | Thrombocytopenia *, Neutropenia *, Anaemia *, Leukopenia * |
| Immune system disorders | | Haemophagocytic lymphohistiocytosis |
| Metabolism and nutrition disorders | | Hypocalcaemia * |
| Nervous system disorders | | Headache *, Paraesthesia |
| Cardiac disorders | | Tachycardia * |
| Respiratory, thoracic and mediastinal disorders | | Acute respiratory distress syndrome, Idiopathic pneumonia syndrome *, Epistaxis * |
| Skin and subcutaneous tissue disorders | | Petechiae * |
| General disorders and administration site conditions | | Chills *, Pyrexia * |
| Injury, poisoning and procedural complications | | Delayed neutrophil engraftment *, Infusion related reactions ‡ |
* At least one event was also attributed to autologous haematopoietic stem cell transplantation complications.
† Lymphopenia included CD4 lymphocytes decreased and lymphocyte count decreased.
‡ Infusion related reactions included chills, sinus tachycardia and tachycardia.
Table 2: Adverse reactions attributed to autologous haematopoietic stem cell transplantation complications in patients with transfusion‑dependent β‑thalassemia in study 111 (N=56)
| System organ class | Very common (≥10%) | Common (≥1% ‑ <10%) |
| Infections and infestations | | Pneumonia, Klebsiella sepsis, Sepsis |
| Blood and lymphatic system disorders | Thrombocytopenia, Febrile neutropenia, Neutropenia, Anaemia, Lymphopenia *, Leukopenia | Splenomegaly |
| Metabolism and nutrition disorders | Decreased appetite, Hypokalaemia, Fluid retention, Hypophosphataemia | Hypoalbuminaemia, Hypomagnesaemia, Hypocalcaemia |
| Nervous system disorders | Headache | Cerebellar haemorrhage, Hydrocephalus, Neuralgia |
| Eye disorders | | Vision blurred |
| Cardiac disorders | | Tachycardia |
| Vascular disorders | | Hypotension |
| Respiratory, thoracic and mediastinal disorders | Epistaxis | Idiopathic pneumonia syndrome, Oropharyngeal pain, Cough, Dyspnoea |
| Gastrointestinal disorders | Mucositis †, Nausea, Abdominal pain ‡, Vomiting, Diarrhoea, Constipation | Colitis, Gastritis, Gingival bleeding, Dyspepsia, Dysphagia, Gastrointestinal inflammation, Haematochezia, Mouth ulceration |
| Hepatobiliary disorders | Veno-occlusive liver disease, Alanine aminotransferase increased | Hepatomegaly, Aspartate aminotransferase increased, Gamma‑glutamyltransferase increased, Hyperbilirubinaemia |
| Skin and subcutaneous tissue disorders | Alopecia, Petechiae, Pigmentation disorder § | Rash #, Dry skin, Pruritus, Erythema |
| Musculoskeletal and connective tissue disorders | Musculoskeletal pain ** | Arthralgia |
| Renal and urinary disorders | | Haematuria |
| Reproductive system and breast disorders | | Amenorrhoea, Premature menopause |
| General disorders and administration site conditions | Pyrexia, Fatigue | |
| Investigations | | C‑reactive protein increased, International normalised ratio increased, Weight increased |
| Injury, poisoning and procedural complications | | Delayed neutrophil engraftment, Subcutaneous haematoma |
* Lymphopenia included CD4 lymphocytes decreased and lymphocyte count decreased.
† Mucositis included anal inflammation, mucosal inflammation, pharyngeal inflammation and stomatitis.
‡ Abdominal pain included abdominal pain lower, abdominal pain upper, abdominal tenderness and epigastric discomfort.
§ Pigmentation disorder included skin hyperpigmentation.
# Rash included dermatitis, rash erythematous and rash maculo‑papular.
** Musculoskeletal pain included back pain, bone pain, chest pain and pain in extremity.
Study 141 (patients 5 years to less than 12 years of age)
The median (min, max) duration of follow‑up for 15 patients after Casgevy infusion was 16.0 (2.2, 24.3) months.
The safety profile of Casgevy was generally consistent with that expected with the myeloablative conditioning regimen used, autologous haematopoietic stem cell transplant, and the safety profile observed in study 111. One patient died due to veno-occlusive disease with subsequent multi-organ failure and pneumonia. The death was not considered to be related to Casgevy.
Description of selected adverse reactions
Platelet engraftment in patients with transfusion-dependent β‑thalassemia (study 111 and study 141)Platelet engraftment is defined as 3 consecutive measurements of platelet counts ≥ 20 × 109/L in patients with transfusion‑dependent β‑thalassemia, obtained on 3 different days after Casgevy infusion without administration of platelet transfusions for 7 days.
In study 111, the median (min, max) time to platelet engraftment was 43.5 (20, 200) days for patients aged 12 years and older (n=56), 45 (20, 199) days in patients aged 12 years to less than 18 years, and 39.5 (24, 200) days in patients aged 18 years and older. Patients without a spleen had an earlier median time to platelet engraftment than patients with an intact spleen. Median (min, max) time to platelet engraftment was 34.5 (20, 78) days in patients without a spleen and 46 (27, 200) days in patients with an intact spleen.
In study 141, the median (min, max) time to platelet engraftment was 51 (22, 82) days for patients aged 5 years to less than 12 years (n=14). 13 of those patients had an intact spleen.
Neutrophil engraftment in patients with transfusion‑dependent β‑thalassemia (study 111 and 141)
Neutrophil engraftment is defined as 3 consecutive measurements of absolute neutrophil count (ANC) ≥ 500 cells/µL on 3 different days after Casgevy infusion, without use of the unmodified rescue CD34+ cells.
In study 111, the median (min, max) time to neutrophil engraftment was 29 (12, 56) days for patients aged 12 years and older (n=56), 30 (19, 56) days in patients 12 to less than 18 years, and 28.5 (12, 40) days in patients 18 years and older.
In study 141, the median (min, max) time to neutrophil engraftment was 30 (19, 38) days for patients aged 5 years to less than 12 years (n=15).
In studies 111 and 141, all patients achieved neutrophil engraftment, and no patients received rescue CD34+ cells.
Patients with sickle cell disease
Summary of the safety profile
Study 121 (patients 12 years and older)
The median (min, max) duration of follow‑up for the 46 patients with sickle cell disease in study 121 after administration of Casgevy, including the follow‑up in study 131 was 44.7 (8.9, 73.7) months.
There were not any serious adverse reactions attributed to Casgevy. There were not any cases of graft versus host disease, graft failure, or graft rejection.
One (2.2%) patient died due to COVID‑19 disease and myeloablative conditioning‑related lung toxicity. The event was not related to Casgevy.
Tabulated list of adverse reactions
Adverse reactions are listed by MedDRA body system organ class and by frequency. Frequencies are defined as: very common (≥ 1/10) and common (≥ 1/100 to <1/10). Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.
Tables 3 and 4 list adverse reactions attributed to Casgevy and autologous haematopoietic stem cell transplant complications, respectively, experienced by patients with sickle cell disease in clinical studies with Casgevy.
Table 3: Adverse reactions attributed to Casgevy in patients with sickle cell disease in study 121 (N=46)
| System organ class | Very common (≥10%) | Common (≥1% ‑ <10%) |
| Blood and lymphatic system disorders | Lymphopenia *, † | Thrombocytopenia *, Neutropenia * |
| Skin and subcutaneous tissue disorders | | Rash *, ‡ |
* At least one event was also attributed to autologous haematopoietic stem cell transplantation complications.
† Lymphopenia included CD4 lymphocytes decreased.
‡ Rash included dermatitis.
Table 4: Adverse reactions attributed to autologous haematopoietic stem cell transplantation complications in patients with sickle cell disease in study 121 (N=46)
| System organ class | Very common (≥10%) | Common (≥1% ‑ <10%) |
| Infections and infestations | | Pneumonia, Sepsis, Oral candidiasis, Folliculitis |
| Blood and lymphatic system disorders | Febrile neutropenia, Thrombocytopenia, Neutropenia, Anaemia, Lymphopenia *, Leukopenia | Pancytopenia, Reticulocytopenia |
| Metabolism and nutrition disorders | Decreased appetite, Hypokalaemia, Hyperphosphataemia, Hypomagnesaemia | Hypophosphataemia |
| Nervous system disorders | Headache | Peripheral sensory neuropathy, Dysgeusia, Neuropathy peripheral |
| Eye disorders | | Dry eye |
| Cardiac disorders | | Tachycardia |
| Vascular disorders | | Hot flush |
| Respiratory, thoracic and mediastinal disorders | Oropharyngeal pain, Epistaxis | Respiratory failure †, Hypoxia |
| Gastrointestinal disorders | Mucositis ‡, Nausea, Vomiting, Abdominal pain §, Diarrhoea, Constipation, Gastritis | Dyspepsia, Gastrooesophageal reflux disease, Haematemesis, Oesophagitis |
| Hepatobiliary disorders | Hyperbilirubinaemia, Alanine aminotransferase increased | Aspartate aminotransferase increased |
| Skin and subcutaneous tissue disorders | Pigmentation disorder #, Skin exfoliation, Alopecia, Dry skin, Rash ** | Pruritus |
| Musculoskeletal and connective tissue disorders | | Musculoskeletal pain †† |
| Renal and urinary disorders | | Dysuria |
| Reproductive system and breast disorders | Amenorrhoea | Intermenstrual bleeding, Vulvovaginal pain, Dysmenorrhoea, Menstruation irregular |
| General disorders and administration site conditions | Pyrexia, Fatigue | Pain |
| Investigations | Weight decreased | International normalised ratio increased |
| Injury, poisoning and procedural complications | | Skin abrasion, Skin laceration |
* Lymphopenia included CD4 lymphocytes decreased and lymphocyte count decreased.
† One patient died due to COVID‑19 disease and conditioning‑related lung toxicity. The event was considered not related to Casgevy.
‡ Mucositis included anal inflammation, mucosal inflammation, pharyngeal inflammation and stomatitis.
§ Abdominal pain included abdominal discomfort, abdominal pain upper and abdominal tenderness.
# Pigmentation disorder included nail pigmentation, skin hyperpigmentation and skin hypopigmentation.
** Rash included dermatitis, rash macular, rash maculo‑papular and rash papular.
†† Musculoskeletal pain included back pain and pain in extremity.
Study 151 (patients 5 years to less than 12 years of age)
The median (min, max) duration of follow‑up for 11 patients after Casgevy infusion was 16.9 (7.6, 24.3) months.
The safety profile of Casgevy was generally consistent with that expected with the myeloablative conditioning regimen used, autologous haematopoietic stem cell transplant and the safety profile observed in study 121.
Description of selected adverse reactions
Platelet engraftment in patients with sickle cell disease (study 121 and study 151)
Platelet engraftment is defined as 3 consecutive measurements of platelet counts ≥50 × 109/L in patients with sickle cell disease, obtained on 3 different days after Casgevy infusion without administration of platelet transfusions for 7 days.
In study 121, the median (min, max) time to platelet engraftment was 34.5 (23, 126) days for patients aged 12 years and older (n=46), 44.5 (23, 81) days in patients aged 12 to less than 18 years, and 32 (23, 126) days in patients 18 years and older.
In study 151, the median (min, max) time to platelet engraftment was 47 (24, 78) days for patients aged 5 years to less than 12 years (n=11).
Neutrophil engraftment in patients with sickle cell disease (study 121 and study 151)
Neutrophil engraftment is defined as 3 consecutive measurements of ANC ≥ 500 cells/µL on 3 different days after Casgevy infusion, without use of the unmodified rescue CD34+ cells.
In study 121, the median (min, max) time to neutrophil engraftment was 27 (15, 40) days for patients 12 years and older (n=46), 28 (24, 40) days in patients aged 12 to less than 18 years, and 26 (15, 38) days in patients 18 years and older.
In study 151, the median (min, max) time to neutrophil engraftment was 28 (20, 37) days for patients aged 5 years to less than 12 years (n=11).
In studies 121 and 151, all patients achieved neutrophil engraftment, and no patients received rescue CD34+ cells.
Long‑term follow-up study 131 (patients with transfusion‑dependent β‑thalassemia or sickle cell disease)
Patients who completed or discontinued studies 111 or 121 were encouraged to enrol in study 131, an ongoing long‑term follow‑up study for a total period of 15 years after Casgevy infusion. An interim analysis of study 131 included 55 patients with transfusion‑dependent β‑thalassemia and 45 patients with sickle cell disease, with follow‑up of up to 58.6 and 49.5 additional months, respectively, beyond the initial 24‑months in studies 111 and 121.
At the time of the interim analysis, (data cut of 13 November 2025 for study 111, and 20 July 2025 for study 121) no new safety concerns were observed.
Paediatric population
The safety profile was generally consistent among paediatric, (aged 5 years to less than 18 years) and adult (aged 18 years and older) patients.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:
Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.